Remote patient monitoring startup Sentrian has partnered with the Scripps Translational Science Institute to study 1,000 chronic obstructive pulmonary disease (COPD) patients. The one-year study will use biosensors to continuously monitor patients and analyze that data to offer alerts for any deterioration. The intention is to intervene before an even becomes acute and requires hospitalization.
An app compatible with Apple's HealthKit launched a pilot program with New York City's Icahn School of Medicine at Mount Sinai, in attempt to help patients self-manage COPD.
The European Respiratory Society and American Thoracic Society have joined forces to highlight what we don't know about COPD in order to steer future research programs in the right way.
Pleasanton, CA's Spirometrix raised $8.6 million in funding for a sensor to detect and treat asthma and COPD, in a round led by Japan's NGK Spark Plugs, which gave $5 million.
Data from a study on a new nondrug treatment for chronic obstructive pulmonary disease offered evidence that Trudell Medical's Aerobika OPEP hand-held device is beneficial for COPD patients with recurring mucus buildup.
Boehringer Ingelheim met its main goals in a late-stage study on a new COPD treatment, clearing the way for regulatory approvals and a bout with rival GlaxoSmithKline.
AstraZeneca was forced to concede a clinical defeat on Monday, noting that one of its top respiratory drugs in the clinic failed a study for severe chronic obstructive pulmonary disease. But while investigators also flagged a higher rate of adverse events for benralizumab than the placebo arm, the pharma giant shows no signs of backing away from a treatment it's billed as a potential $2 billion per year product.
It can be difficult for patients with respiratory ailments to track their use of rescue medications. An inhaler sensor from Propeller Health does just that--serving as a remote monitor of drug use and feeding into a mobile app that tracks and analyzes medication use. The app even predicts when patients are likely to have difficulty, based on prior experience, and can be used to ensure proper inhaler usage, a common issue.
The FDA's Pulmonary-Allergy Drugs Advisory Committee voted 10-3 to recommend approval of Boehringer Ingelheim's mist formulation of its dry-powder inhalable treatment for chronic obstructive pulmonary disease.
The COPD market has its fair share of contenders, but that's not stopping Boehringer Ingelheim from joining the party. The German drugmaker has nabbed FDA approval for its own entrant, which will go up against the likes of Glaxo's aging giant Advair in a market-share showdown. But despite the competition, BI is hoping it can still find its corner.